BioCentury | Jun 8, 2015
Company News

Santen sales and marketing update

...Health Care (IQWiG) said that added benefit cannot be derived for the fixed combination of Tapcom...
...noted that there was no information about patients who had been pretreated with beta-blocker monotherapy. Tapcom...
BioCentury | May 19, 2014
Company News

Merck, Santen deal

...and Saflutan tafluprost, a preservative-free, synthetic analog of prostaglandin F2 alpha. The deal also includes Taptiqom...
...and Saflutan tafluprost, a preservative-free, synthetic analog of prostaglandin F2 alpha. The deal also includes Taptiqom...
Items per page:
1 - 2 of 2